Evidenced-based guidelines for tuberculosis screening before biologic treatment initiation

J Am Acad Dermatol. 2020 Jul;83(1):e25-e26. doi: 10.1016/j.jaad.2020.02.084. Epub 2020 Mar 25.

Authors

Payal Shah¹, Gabriel Rebick², Shirin Bajaj³, Ludovic Desvignes², Kristen Lo Sicco³

Affiliations

¹ The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York. Electronic address: [email protected].
² Department of Medicine, Division of Infectious Diseases and Immunology, New York University Langone Health, New York, New York.
³ The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York.

PMID: 32222451
DOI: 10.1016/j.jaad.2020.02.084

No abstract available

Publication types

Letter
Comment

MeSH terms

Biological Products*
Hidradenitis Suppurativa*
Humans
Latent Tuberculosis* / diagnosis
Latent Tuberculosis* / drug therapy
Mass Screening
Psoriasis*

Substances

Biological Products